Imunon, Inc. IMNN
Imunon, Inc. (Nasdaq: IMNN) is an oncology drug developer. Its lead program, IMNN-001 (TheraPlas IL-12 DNA immunotherapy), is in Phase 3 for Newly diagnosed advanced (stage III/IV) ovarian cancer, with neoadjuvant/adjuvant chemotherapy. Its next catalyst on record is IMNN-001: Complete ITT enrollment in Phase 3 OVATION 3 (H1 2029).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IMNN-001 — Complete ITT enrollment in Phase 3 OVATION 3 (H1 2029). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IMNN-001 OVATION 3 (pivotal) | Newly diagnosed advanced ovarian cancer | gene therapy | Phase 3 |
| IMNN-001 + bevacizumab MRD study (Break Through Cancer) | Advanced ovarian cancer, minimal residual disease | gene therapy | Phase 2 |
| IMNN-101 (PLACCINE DNA COVID-19 booster vaccine) | SARS-CoV-2 seasonal booster | vaccine | Phase 1 |
Recent results and decisions
- Oct 21, 2026n/a VoxelDox intends to initiate a Phase 1 clinical trial in glioblastoma patients following a planned $2.5 million financing.
Closing of the transaction is contingent upon VoxelDox completing a planned $2.5 million financing to support initiation of a Phase 1 clinical trial in patients with glioblastoma.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.